[Helicobacter pylori and nonspecific intestinal inflammation].
In 50 subjects with non-specific inflammations of the gut the total prevalence of Helicobacter pylori positive antibodies was 28%, while in the control group of blood donors its was 54% Patients with ulcerative colitis had lower antibodies--18%, in Crohn's disease the serum positivity was 33%. The lowest value of antibodies was found in patients taking Sulfasalazine--11%. The serum positivity was substantially higher in inactive ulcerative colitis and Crohn's disease--35% than in patients with signs of high activity--13%. In 28 patients with non-specific inflammations of the gut endoscopy was performed, in 60% with a pathological outcome. Histologically confirmed gastritis was in the majority Helicobacter pylori negative. It may be stated that in patients with non-specific inflammations of the gut there is a lower incidence of Helicobacter pylori than in the general population, in particular those subjects who were or are treated with Sulfasalazine. The explanation of this fact is however only speculative.
Münzová
H
H
Pracovistĕ Bohunice, Interní gastroenterologická klinika FN Brno.
Dítĕ
P
P
Sevcíková
I
I
Dolina
J
J
Novotný
I
I
Kunovská
M
M
D000293:Adolescent; D000328:Adult; D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000907:Antibodies, Bacterial / Q000097:blood*; D003093:Colitis, Ulcerative / Q000188:drug therapy / Q000382:microbiology*; D003424:Crohn Disease / Q000188:drug therapy / Q000382:microbiology*; D005260:Female; D016481:Helicobacter Infections / Q000150:complications / Q000175:diagnosis; D016480:Helicobacter pylori / Q000276:immunology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012698:Serologic Tests; D012460:Sulfasalazine / Q000627:therapeutic use
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000907:Antibodies, Bacterial; D012460:Sulfasalazine
Helicobacter pylori a nespecifické strevní zánĕty.